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Abstract 
Background SBTx has become a feasible therapeutic option for 
patients with irreversible intestinal failure. Increase in the number and in the 
European Scientific Journal April 2016 edition vol.12, No.12  ISSN: 1857 – 7881 (Print)  e - ISSN 1857- 7431 
2 
improvement of the patient and graft survival in SBTx has a slow course 
when compared to other solid organ transplantation. 
Aim The aim of this study is to analyze 25 isolated SBTx performed since 
2003 at a single center. It also aims to compare the patient and graft survivals 
rate during the early (before 2010) and late (after 2010) period.  
Materials and Methods Medical charts of 24 patients were analyzed 
retrospectively. To compare the center’s experience during a twelve year 
period, the results were divided into two groups (before (n:7) and after 2010 
(n:18)). At the appropriate time, data were reported as mean± standard 
deviation, median, and range. Kaplan Meier method was used for the 
survival analysis of the graft and the patients. 
Results Median age of the patients was 39 (min 6 months, max: 56 yr). Six 
of them were in the pediatric age group.  Compared to before 2010, graft 
survival rates increased from 28.1% to 53.8% in 3 months, from 28.6% to 
35.9% in 6 months, and from 14.3% to 29.9% in one year after 2010. At the 
same period, patient survival rate increased from 57.1% to 72.2% in 3 
months, from 28.6% to 38.9% in 6 months, and from 14.3% to 33.3% in one 
year. In the pediatric age group, patient and graft survival rates were 85.7% 
in 3 months, 71.4% in 6 months, and 71.4 % in 1 year. 
Conclusion SBTx is an effective treatment choice for selected patients with 
intestinal failure. Although patient and graft survival rates were improved 
after 2010 in our center, it was inferior. Patient and graft survival rates in 
pediatric SBTx are favourable and promising. 
 
Keywords: Small bowel transplantation, isolated small bowel 
transplantation, intestinal failure, graft survival, patient survival, turkey 
 
Introduction 
 Intestinal failure (IF) is defined as the state of the intestinal function 
which is below the minimum requirement for the absorption of 
macronutrients, water, and electrolytes (Kaufmann et al., 2015). However, 
underlying causes of intestinal failure may be divided into three main 
categories, namely: short bowel syndrome, motility disorders, and primary 
mucosal disorders (Gupte et al., 2006). The patients with intestinal failure 
have to be administered Total Parenteral Nutrition (TPN) through the central 
venous access. Thus, through the help of Total parenteral support, patient’s 
survival rates have increased. On the other hand, TPN have introduced new 
problems like parenteral nutrition associated liver disease, vascular access 
problems, and cathater associated life threating blood stream infections 
(Touloukian et al., 1973). Despite the advancement, contemporary 
multicenter studies stated that 19-26% of TPN dependent patients develop 
severe complications; also, they have indications for Small bowel 
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transplantation (SBTx) (Pironi et al., 2011; Squires et al., 2012). In addition, 
for patients with irreversible intestinal failure, SBTx has become a feasible 
therapeutic option (Furukawa et al., 1997).  
 During the past two decades through the technical innovations in 
surgery, improved postoperative care, achievement of efficient prevention, 
treatment, and/or control of rejection, and the outcomes of SBTx have been 
improved (Abu-Elmagd et al., 2001). However, it is still a challenging 
procedure due to strong organ immunogenity (Ceulemans et al., 2015). Till 
now, 2887 transplants on 2699 patients have been performed worldwide 
(Grant et al., 2015). Thus, one year graft failure rate is still high (29%) for 
patients who were transplanted since 2000 (Grant et al., 2015). Although, the 
mortality and morbidity rates of intestinal transplant recipients are similar to 
permanent TPN patients, the rate of graft failure beyond 1 year is yet to be 
improved (Grant et al., 2015; Ueno et al., 2011).  
 At Tepecik training and research hospital, 25 isolated SBTx on 24 
patients were performed as at December 2003.  In the present study, we 
reported a single center with twelve years of experience on SBTx. 
 
Materials and Methods 
 Medical charts of 24 patients which underwent 25 isolated SBTx 
since 2003 were analyzed retrospectively. Donor and recipient demographic 
data which include cold ischemia time, number of HLA mismatch, cause of 
intestinal failure, blood groups, immunosupressive treatment, acute rejection 
rates, cause of graft and patient loss, and patient follow-up data were 
recorded. Therefore, comparing the center’s experience (preoperative and 
postoperative care, ICU, rejection management, etc.) during a twelve year 
period, the results were divided into two groups (before (n:7) and after 2010 
(n:18)).  Only isolated SBTx were performed in our center.  
 
Statistical Analysis 
 Statistical Package for Social Sciences (SPSS) version 22 (USA) was 
used for the whole statistical analysis.  At the appropriate time, data were 
reported as mean±standard deviation, median, and range. P value of less than 
0.05 was considered to be significant. Chi-squared and Fischer Exact tests 
were performed to compare demographic covariates between groups, when 
appropriate. Mann-Whitney U test was used to assess the differences in rank 
distributions of continuous variables between two groups. Consequently, 
Kruskal Wallis test was used to compare variables among three different 
groups. In addition, Kaplan-Meier method was used for the survival analysis 
of the graft and the patients.  
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Results 
 Twenty five isolated SBTx were performed for 24 patients since 
2003. Thus, all the patients were suffering from life threating complications 
(vascular access problems, recurrent cathater infections, fungal infections, 
etc.) due to irreversible intestinal failure. Liver disease (mild fibrosis) 
associated with Parenteral nutrition was observed in three patients. None of 
the patients had irreversible intestinal failure. All the patients were under 
treatment, and were followed up at the hospital prior to the transplantation.  
 
Recipient Characteristics 
 The median age of the patients was 39 (min 6 months, max: 56 yr). 
Fourty eight percent (n:12) of the patients were female. Six of them (25%) 
were in the pediatric age group. However, the main causes of intestinal 
failure were mesenteric artery thrombosis (83%, n:15) in adult patients and 
malrotation (n:2) and waanderburg syndrome(n:2) in pediatric patients. 
Mean cold ischemia time was 368 + 115 min. Median waiting time was 3 
months (min 1 day, max: 12 months). Also, retransplantation was performed 
for only one patient who had graft lost due to chronic rejection in 45 months. 
Bone marrow mesenchimal stem cell (BMSCs) therapy was introduced to 8 
patients (3 pediatric patients) beside SBTx. However, our BMSCs procedure 
was previously described elsewhere (Dogan et al., 2014).  
 
Donor Characteristics 
 All intestinal grafts were recovered from heart beating brain death 
donors. Median age of the donors was 33 (min: 3 yr, max: 60 yr). Sixteen of 
the 25 donors were male. Mean BMI of the donors was 24+ 3 kg/ m2 (min: 
10,4 , max 31.9).  Thus, the most common cause of brain death was 
traumatic/spontaneous subarachnoid bleeding (84%). Fifty two percent 
(n:14) of the donors were obtained from regional sharing. Also, median ICU 
stay was for 3 days (min: 1, max: 12 days).  
 
Immunologic Parameters 
 Complement dependent cytotoxicty (CDC) and Flow cytometry 
cross-match were negative for all patients. Only one patient was introduced 
to a desentisitation protocol (Intravenous Immunoglobuline + 
Plashmapherase and rituximab) due to high Panel reactive antibodies (PRA) 
levels and recurrent cross match positivity (Gondolesi et al., 2006).  
However, this patient died after one month of transplantation due to 
refractory acute rejection and sepsis. Blood group compatible intestinal graft 
was used in three SBTx. The median number of HLA mismatch was 4.  
 
 
European Scientific Journal April 2016 edition vol.12, No.12  ISSN: 1857 – 7881 (Print)  e - ISSN 1857- 7431 
 
 
5 
Surgical Technique 
 Before the harvesting, colistin, gentamycin, and fungostatin infusion 
was introduced via gastric tube into donor’s small bowel for the last five 
cases. In early cases, gastric tube lavage and intragastric antibiotic and anti-
fungal treatment was not introduced. However, we used only the solution 
from the University of Wisconsin (UWTM) for organ perfusion. Also, only 
static cold storage technique was used for organ storage.  
 Median number of previous abdominal operation was three. Eighteen 
of the patients had ultra-short segment of intestine. Open abdomen was 
observed for 8 patients prior to transplantation. Ileojejunal graft was used for 
all adult recipients. Jejunal graft was used for only one pediatric recipient. 
Colon segment was not used for any recipients. Superior mesenteric artery 
was anostomosed to infra renal aorta. Thus, superior mesenteric vein 
anostomosis was performed on infra renal vena cava by end to side fashion. 
Extension graft was not used. Proximal gastrointestinal continuity was 
established by jejunoduedenal anostomosis. A simple ostomy was performed 
for the distal end. Gastrojejunal feeding tube was introduced for enteral 
support for all patients. In addition, ostomy was taken down at the first year 
after transplantation.   
 
Immunsupression 
 Induction treatment contained Rabbit anti-thymocyte globulin 
(rATG-Fresenius®) (n: 23,91%, total dose 10 mg/kg) or Basiliximab (n:2, 
8.7%, at 0 and 4 days) and steroid (10 mg/kg). Rituximab (375 mg/kg) was 
used prior to SBTx on the one hypersentisized patient. After transplantation, 
tacrolimus is used for all patients until the observed bowel movement. Thus, 
this is followed by oral tacrolimus treatment. Main immunosuppression has 
an high dose tacrolimus (Prograf TM, 15-20 ng/ml) in the first month period. 
Maintenance therapy included tacrolimus (12-15 ng/ml in first two months 
and 8-10 ng/ml in following months) and low dose steroid (for 9 months). 
After two months, sirolimus (n: 23) or everolimus (n:2) (3-8 ng/ml) were 
added.  Immunosuppression protocol for acute cellular rejection (ACR) 
includes high dose steroid, rATG therapy, and/or intravenous 
immunoglobulin (IVIG). Besides, we used TNF-blocker (Remicade®, 
Janssen Biotech, Inc.) in one patient with the chronic rejection.  
 
Follow Up and Graft-patient Survival 
 Graft monitoring by endoscopy after transplantation by ostomy, twice 
in the first two weeks than after endoscopic examination, was done 
periodically for one week interval until the second month. 
 Median patient follow up was 8 months before 2010, and 11 months 
after 2010. When SBTx were grouped as before and after 2010, it was seen 
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that pediatric transplantations and the use of BMSCs have begun. Therefore, 
organ retrieving from regional sharing was higher in the second period.  
There was no statistically significant difference among the two groups. 
Subsequently, Table 1 summarizes the comparison of the patient and donor 
demographic data among two groups.  
 When compared to before 2010, graft survival rates were increased 
from 28.1% to 53.8% in 3 months, from 28.6% to 35.9% in 6 months, and 
from 14.3% to 29.9% in one year after 2010. At the same period, patient’s 
survival was increased from 57.1% to 72.2% in 3 months, from 28.6% to 
38.9% in 6 months, and from 14.3% to 33.3% in one year. In the pediatric 
age group which begun after 2010, patient and graft survival rates were 
85.7% in 3 months, 71.4% in 6 months, and 71.4 % in 1 year.   
 
Discussion 
 Increase in the number and improvement of the patient and graft 
survival rate in SBTx has a slow course compared to the other solid organ 
transplantations.  The complexity of the management and treatment of acute 
rejection with a lymphoid rich content, have an important role to play in this 
situation (Abu-Elmagd et al., 2001). Although due to these difficulties, in the 
last two decades, SBTx has been a feasible treatment of choice for patients 
with irreversible intestinal failure. However, they suffer from life threating 
complications associated with total parenteral nutrition.  
 2887 SBTx on 2699 patients were performed in 82 transplant centers 
between 1985 and February 2013 according to the Intestinal Transplant 
Registry (ITR) (Grant et al., 2015). Furthermore, seventy six percent of the 
world SBTx activity was carried out in North America. Most of the SBTx 
were performed in few centers and less than half of the transplant centers are 
currently active. Between 2009 and 2013, the number of transplant centers 
that performed at least one SBTx were 47. Twenty seven transplant centers 
were closed due to the SBTx programs during the same period (Grant et al., 
2015). Unfortunately, except for North America, the SBTx activity has not 
increased. Also, low volume SBTx in many developed countries needs more 
attention (Celemans et al., 2015; Di Benedetto et al., 2005; Pascher et al., 
2005; Soin et al., 2014). Therefore, this present study is important owing to 
the report of the experience of a small volume transplant centers in a 
developing country. Our Center is the most active. Therefore, there is only 
one pediatric SBTx center in Turkey, and the number of SBTx have been 
increasing since the last two years.  
 Previously, lopushinsky et al suggested that when SBTx is 
indispensable, it should be performed before the development of the 
irreversible liver failure (Lopushinsky et al., 2007).  According to Intestinal 
transplant registry report, isolated SBTx without liver is recently in the trend 
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of increase (Grant et al., 2015). In our series, three of the patients were 
suffering from reversible liver failure. Thus, none of the patients had any 
complications associated with the liver failure.  
 Furthermore, it was shown that waiting at home is related to better 
graft survival rates in SBTx (Grant et al., 2015). Seventy two percent of the 
patients that underwent SBTx between 2001 and 2011 were waiting at home. 
Most especially, South America and Asia transplant centers performed SBTx 
for sicker patients (63 % and 79 % of the patients were at home prior to 
transplantation) (Grant et al., 2015). In Turkey, there is no well-established 
active home parenteral nutrition program for patients with intestinal failure. 
In our series, all the patients were under treatment at the hospital prior to 
SBTx.   
The main cause of the patient’s lost in SBTx is sepsis (%50). Acute 
rejection (13%) and cardiovascular events (8%) are other cause of patient’s 
lost in SBTx (Grant et al., 2015).  The risk of bacterial infection in the first 
year was reported as 90-100 % previously. Thus, the risk of fungal infection 
is reported as 30-50% at the same period (Mangus et al., 2013). Mucosal 
barrier impairment which induced bacterial translocation during acute 
rejection episode was accused for the increase in severity and the frequency 
of sepsis (Middleten et al., 2005). The relation of sepsis and acute rejection is 
seen as the most important cause of patient’s and graft lost. In the present 
study, sepsis was the most common cause of patient lost as well (%.47, N:9).  
 The diagnosis and the treatment of the acute rejection is still an 
unresolved problem in SBTx (A Hilmi et al., 2013). Between 2005 and 2008, 
the percentage of SBTx recipients treated for acute rejection is 30-40 % 
(Mazariegos et al., 2010). Thus, it was reported as 80% the last year (David 
et al., 2007). In our series, the rate of acute rejection was 43% before 2010, 
and was 33% after 2010.  
 The currently used tools for the diagnosis of the acute rejection in 
SBTx are clinic findings, endoscopic follow up, and biopsy evaluation (A 
Hilmi et al., 2013).  The first 30 days after SBTx is very significant term for 
the occurrence of acute rejection (Ceulemans et al., 2015). This situation 
emphasizes the importance of induction treatment. Recent studies show that 
the use of anti-thymocyte globulin, anti-interleukin receptor blockers and 
alemtuzumab, decreases the rate of acute rejection (A Hilmi et al., 2013; 
Sudan et al., 2014). According to OPTN/SRTR 2011 annual report, 75 % of 
the SBTx recipients have introduced the induction treatment (Sudan et al., 
2013). In another study that compares the effectiveness of the induction 
protocols for the prevention of acute rejection, it shows that the use of 
antilymphocyte globuline reduces the ACR but increases the infection rates 
(Trevizol et al., 2012). 
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 According to SRTR data, in 1998, one year graft and patient survival 
was 52% and 69%. Thus, these rates became 75% and 79% in 2007, 
respectively (A Hilmi et al., 2013). When the SRTR intestinal scientific 
report (between 2012 and 2014) was analyzed, one year graft and patient 
survival rates were seen at the range of 25% and 95% depending on the 
patient volume (SRTR, 2015). In the present study, one year graft and patient 
survival rates have been improved after 2010 (from 14.3% to 29.9% and 
from 14.3% to 33.3% respectively). Although the results have been 
improved by the time, graft and patient survival is still inferior compared to 
SRTR data. Nevertheless, one year graft and patient’s survival rates in 
pediatric patients (71.4%) were favourable with the registry data. It seems 
that the improvement of the survival rates after 2010 is mainly dependent on 
the better outcomes of pediatric patients.  
 
Conclusion 
 In conclusion, SBTx is an effective treatment choice for selected 
patients with intestinal failure. Although patient and graft survival rates are 
improved after 2010 in our center, it is still inferior. Patient and graft 
survival rates in pediatric SBTx are favourable and promising. 
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Table Legends 
Table 1. Comparison of the patient and donor demographic data among two groups (before 
and after 2010) 
 Before 2010 After 2010 P value 
Recipient age (yr) 37+8 33+18 0.319 
Pediatric cases n: 0 n:6 0.001 
Recipient weight (kg) 57+14 49+24 0.517 
Recipient BMI 21+0.7 25+7 0.287 
Cause of Intestinal 
failure 
Mesenteric artery 
trombosis 
Waanderburg 
Syndrome 
Malrotation 
Crohn disease 
Burger disease 
Traumatic injury 
Surgical complication 
Chronic rejection: 
 
n:5 
n: 0 
n: 0 
n:1 
n: 1 
n:0 
n:0 
n:0 
 
n:11 
n:2 
n:2 
n: 
n: 
n: 1 
n: 1 
n:1 
0.444 
Mesenchimal stem cell 
infusion 
n: 0 n: 8 0.001 
Induction Treatment 
Basiliximab/ATG 
 
n: 2/5 
 
n: 1/17 
0.311 
Blood group 
Identical/competable 
 
n: 6/1 
 
n: 14/4 
0.312 
Acute Rejection n: 3 n: 6 0,656 
Cold ischemia time 240+160 396+84 0.053 
Duration of operation 330+64 475+87 0.141 
Donor Center 
İzmir/ Regional 
 
n: 5/2 
 
n: 6/12 
0.008 
Waiting time (days) 20 days 89 days 0.333 
Postoperative hospital 
stay 
52 days 84 days 0.386 
Donor Age 32+13 36+16 0.242 
Donor Gender 
Woman/Man 
 
n: 3/4 
 
n: 6/12 
0.854 
Donor Weight 65+7 69+19 0.338 
Cause of Brain Death 
Traumatic 
/spontaneous Brain 
injury 
Other 
 
n:5 
n:2 
 
n:15 
n:3 
0.773 
ICU Stay (day) 2.5+0.7 3.5+2.9 0.918 
Cardiac arrest 
(Yes/No) 
2/5 3/15 0.484 
Cause of Recipient 
death 
Sepsis 
Acute rejection 
Pulmonary Embolia 
PTLD 
Graft thrombosis 
 
n:3 
n:0 
n:1 
n:0 
n:2 
 
n:6 
n:2 
n:1 
n:1 
n:3 
0.632 
  
